Back to resultsA Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
Primary Purpose
Anxiety Disorders
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
MK0777
Sponsored by
About this trial
This is an interventional treatment trial for Anxiety Disorders
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of General Anxiety Order
Exclusion Criteria:
- Women who are pregnant or breast-feeding
- History of severe drug reaction
- History of severe drug withdrawal symptoms such as seizures or delirium
- Disease of cardiovascular system
- Disease of the liver, kidneys, endocrine system, metabolic system or eyes
- History of seizures or seizure disorder
- History of drug or alcohol abuse
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00543920
First Posted
October 5, 2007
Last Updated
November 25, 2015
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00543920
Brief Title
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
August 2002 (undefined)
Primary Completion Date
February 2003 (Actual)
Study Completion Date
February 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0777
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of General Anxiety Order
Exclusion Criteria:
Women who are pregnant or breast-feeding
History of severe drug reaction
History of severe drug withdrawal symptoms such as seizures or delirium
Disease of cardiovascular system
Disease of the liver, kidneys, endocrine system, metabolic system or eyes
History of seizures or seizure disorder
History of drug or alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
We'll reach out to this number within 24 hrs